Skip to main content

Table 1 Baseline demographic and clinical characteristics

From: Evaluation of an electronic warfarin nomogram for anticoagulation of hemodialysis patients

  Pre-period
n = 67
Post-period
n = 55
Age, mean (SD) 69.8 (12.8) 69.4 (14.0)
Male (%) 46 (68.7) 34 (61.8)
Diabetes (%) 34 (50.8) 33 (60.0)
Cause of end stage renal disease (%)   
   Diabetes Mellitus 24 (35.8) 23 (41.8)
   Vascular 17 (25.4) 15 (27.3)
   Glomerulonephritis 9 (13.4) 3 (5.5)
   Other 9 (13.4) 8 (11.9)
   Unknown 8 (11.9) 9 (16.4)
Indication for anticoagulation (%)   
   Thromboembolic disease 18 (26.9) 18 (32.7)
   Cerebrovascular disease 1 (1.5) 1 (1.8)
   Atrial fibrillation 31 (46.3) 23 (41.8)
   Vascular access patency 4 (6.0) 2 (3.6)
   Prosthetic valve 3 (4.5) 3 (5.5)
   Unspecified or unknown 10 (14.9) 8 (14.6)
Range INR (%)   
   1.5 to 2.5 14 (20.9) 9 (16.4)
   2.0 to 3.0 51 (76.1) 43 (78.2)
   2.5 to 3.5 2 (3.0) 3 (5.5)
Prior bleed 11 (16.4) 11 (20.0)
Prior thromboembolic event 13 (19.4) 9 (16.4)
Known hereditary thrombotic disease 1 (1.5) 1 (1.8)
Use of Plavix 0 (0.0) 0 (0.0)
Use of NSAIDs or ASA 1 (1.5) 1 (1.8)
History of cancer 10 (14.9) 5 (9.1)
  1. INR - International normalized ratio